A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this observational study is to explore the efficacy of methylphenidate hydrochloride in children and adolescents diagnosed with attention-deficit hyperactivity disorder (ADHD) by Kiddie-scheduled for affective disorders (SADS)-present and life time version (K-SADS-PL).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Korea, Ltd., Korea
• Treatments: Atomoxetine Hydrochloride; Methylphenidate

Criteria

Inclusion Criteria:

• Has been diagnosed with attention-deficit hyperactivity disorder (ADHD) by Kiddie-SADS-present and life time version (K-SADS-PL)

• Have not received methylphenidate or atomoxetine within 3 months prior to screening.

Exclusion Criteria:

• Has intelligence quotient (IQ) ≤70 assessed by comprehensive attention test (CAT) at screening diagnosed with congenital disorders

• Has had history of acquired brain damage (eg, cerebral palsy)

• Has had diagnosed with convulsive disabilities or other neurological disease or dysesthesia

• Has had developmental disabilities such as autistic spectrum disorder

• Has had history of schizophrenia, bipolar, or other pediatric psychotic disorder, and obsessive compulsive disorder

• Has had linguistic disability and had diagnosed with tic disorder that requires additional drug treatment.